Digital health solutions

Complex workflows. Simplified.

Workflow inefficiencies can overburden staff and put patient care at risk. Many health systems struggle to identify eligible patients, which can contribute to gaps in care. Learn how electronic health record (EHR) and technology-enabled optimizations can help deliver efficient and effective care across the cancer screening continuum.

Real-world insights

Our team can help advance your health system with smarter integration and workflow optimizations that deliver actionable results. Implementing workflow enhancements helped NCH increase their CRC screening rate by 23% from 2018 to 2022.1
Having that interface [between our EHR system and Exact Sciences Laboratories] is a dramatic benefit to be able to track down the discrete information of the screening.1
Dr. David Linz
Chief Medical Informatics Officer, NCH

Drive actionable insights

Our approach delivers actionable insights through EHR integrations, workflow optimizations, and performance measurement to help health systems scale cancer screening programs and maximize their technology investments.

Build a strong foundation for screening success

Cancer Screening
Seamlessly integrate with 10+ EHR platforms to support provider workflows and help improve patient care, including patient identification, outreach, metrics, and reporting across:

  • Cologuard Plus® test
  • Cancerguard® multi-cancer early detection test

Precision Oncology
Streamlined test ordering, results reporting and workflow optimization to transform the diagnostic experience within Epic Aura and OncoEMR. Tests available for integration include:

  • Oncotype DX Breast Recurrence Score® test
  • Oncodetect® test
  • OncoExTra® test
  • Riskguard® hereditary cancer test

Identify core enhancements

Identify high impact EHR enhancements to pinpoint eligible patients, close care gaps, and strengthen CRC screening performance across your health system.

Turn data into action

Transform data into measurable action with tailored digital health solutions that enable targeted outreach, patient engagement, and screening activation.

Measure and report

Comprehensive performance measurement and quality reporting show what’s working and where to focus next.

Advance your health system with smarter integration and workflow optimizations.

Learn how to streamline EHR integrations, reduce operational burden, and activate data-driven workflows across your organization.

Optimize your technology investment

Our dedicated digital health teams are here to support you with:

  • A guided implementation experience that simplifies EHR integration and accelerates test deployment.
  • A long-term strategic collaboration focused on workflow improvement, provider adoption, and continuous optimization

A case study for data-driven success

See how a health system increased CRC screening rates from 79% to 84% by leveraging technology to support patient identification, outreach, ordering, and results delivery.2

Real-world examples

Explore our library of case studies that illustrate how our cancer screening tests can help enhance screening efforts within your health system.

Important Information about the Cologuard products


Indications for Use

The Cologuard® and Cologuard Plus® tests are intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced precancerous lesions (APL) and should be followed by a colonoscopy. The Cologuard test and Cologuard Plus test are indicated to screen adults of either sex, 45 years or older, who are at average risk for CRC. These tests are not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

Contraindications

The Cologuard products are not for high-risk individuals, including patients who have the following:

  • a personal history of colorectal cancer or precancerous colon polyps​
  • a positive result from another colorectal cancer screening method within that test's recommended screening interval​
  • have been diagnosed with a condition associated with high risk for colorectal cancer such as inflammatory bowel disease (IBD), chronic ulcerative colitis (UC), Crohn’s disease
  • have a first-degree family history of colorectal cancer, or certain hereditary syndromes

Patients should talk to a healthcare provider if any of these situations apply.


Warnings and Precautions

All positive results should be referred to colonoscopy.

The Cologuard products may produce false positive and false negative results. A false positive result occurs when a result is positive, even though a colonoscopy will not find CRC or APL. A false negative result occurs when a result is negative, even when a colonoscopy identifies APL or CRC.

A negative result does not guarantee the absence of colorectal cancer or advanced adenoma. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Performance when used for repeat testing has not been established.

Refer to the Cologuard test Clinician Brochure or the Cologuard Plus test Clinician Brochure for additional information about the benefits and risks of using each version of the Cologuard product for CRC screening.

Rx only.